Federal Register / Vol. 87, No. 9 / Thursday, January 13, 2022 / Notices 2177 

Statute. The complainant requests that 

the Commission institute an 

investigation and, after the 

investigation, issue a limited exclusion 

order and cease and desist orders. 

ADDRESSES: The complaint, except for 

any confidential information contained 

therein, may be viewed on the 

Commission’s electronic docket (EDIS) 

at https://edis.usitc.gov. For help 

accessing EDIS, please email 

EDIS3Help@usitc.gov. Hearing impaired 

individuals are advised that information 

on this matter can be obtained by 

contacting the Commission’s TDD 

terminal on (202) 205–1810. Persons 

with mobility impairments who will 

need special assistance in gaining access 

to the Commission should contact the 

Office of the Secretary at (202) 205– 

2000. General information concerning 

the Commission may also be obtained 

by accessing its internet server at 

https://www.usitc.gov. 

FOR FURTHER INFORMATION CONTACT: 

Jessica Mullan, Office of the Secretary, 

Docket Services Division, U.S. 

International Trade Commission, 

telephone (202) 205–1802. 

SUPPLEMENTARY INFORMATION: 

Authority: The authority for 

institution of this investigation is 

contained in section 337 of the Tariff 

Act of 1930, as amended, 19 U.S.C. 

1337, and in section 210.10 of the 

Commission’s Rules of Practice and 

Procedure, 19 CFR 210.10 (2021). 

Scope of Investigation: Having 

considered the complaint, the U.S. 

International Trade Commission, on 

January 7, 2022, ordered that— 

(1) Pursuant to subsection (b) of 

section 337 of the Tariff Act of 1930, as 

amended, an investigation be instituted 

to determine whether there is a 

violation of subsection (a)(1)(B) of 

section 337 in the importation into the 

United States, the sale for importation, 

or the sale within the United States after 

importation of certain products 

identified in paragraph (2) by reason of 

infringement of one or more of claims 

1–3, 5, 9–11, 15, and 17–20 of the ’511 

patent; claims 1–8 and 11–20 of the ’705 

patent; claims 1–9, 13–19, and 21 of the 

’749 patent; claims 1, 9, and 14 of the 

’598 patent; claims 1–4 of the ’562 

patent; and claims 11, 12, 14, and 15 of 

the ’932 patent; and whether an 

industry in the United States exists as 

required by subsection (a)(2) of section 

337; 

(2) Pursuant to section 210.10(b)(1) of 

the Commission’s Rules of Practice and 

Procedure, 19 CFR 210.10(b)(1), the 

plain language description of the 

accused products or category of accused 

products, which defines the scope of the 

investigation, is ‘‘footwear with a 

knitted upper or with an upper with 

knitted elements’’; 

(3) For the purpose of the 

investigation so instituted, the following 

are hereby named as parties upon which 

this notice of investigation shall be 

served: 

(a) The complainant is: 

Nike, Inc., One Bowerman Drive, 

Beaverton, OR 97005 

(b) The respondents are the following 

entities alleged to be in violation of 

section 337, and are the parties upon 

which the complaint is to be served: 

adidas AG, World of Sports, AdiDassler-Strasse 1, 91074 

Herzogenaurach, Germany 

adidas North America, Inc., adidas 

Village, 5055 N Greeley Avenue, 

Portland, OR 97217 

adidas America, Inc., adidas Village, 

5055 N Greeley Avenue, Portland, OR 

97217 

(4) For the investigation so instituted, 

the Chief Administrative Law Judge, 

U.S. International Trade Commission, 

shall designate the presiding 

Administrative Law Judge. 

The Office of Unfair Import 

Investigations is not participating as a 

party to this investigation. 

Responses to the complaint and the 

notice of investigation must be 

submitted by the named respondents in 

accordance with section 210.13 of the 

Commission’s Rules of Practice and 

Procedure, 19 CFR 210.13. Pursuant to 

19 CFR 201.16(e) and 210.13(a), as 

amended in 85 FR 15798 (March 19, 

2020), such responses will be 

considered by the Commission if 

received not later than 20 days after the 

date of service by the complainant of the 

complaint and the notice of 

investigation. Extensions of time for 

submitting responses to the complaint 

and the notice of investigation will not 

be granted unless good cause therefor is 

shown. 

Failure of a respondent to file a timely 

response to each allegation in the 

complaint and in this notice may be 

deemed to constitute a waiver of the 

right to appear and contest the 

allegations of the complaint and this 

notice, and to authorize the 

administrative law judge and the 

Commission, without further notice to 

the respondent, to find the facts to be as 

alleged in the complaint and this notice 

and to enter an initial determination 

and a final determination containing 

such findings, and may result in the 

issuance of an exclusion order or a cease 

and desist order or both directed against 

the respondent. 

By order of the Commission. 

Issued: January 10, 2022. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2022–00600 Filed 1–12–22; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—ODVA, Inc. 

Notice is hereby given that, on 

January 4, 2022, pursuant to Section 6(a) 

of the National Cooperative Research 

and Production Act of 1993, 15 U.S.C. 

4301 et seq. (‘‘the Act’’), ODVA, Inc. 

(‘‘ODVA’’) has filed written notifications 

simultaneously with the Attorney 

General and the Federal Trade 

Commission disclosing changes in its 

membership. The notifications were 

filed for the purpose of extending the 

Act’s provisions limiting the recovery of 

antitrust plaintiffs to actual damages 

under specified circumstances. 

Specifically, Asyril SA, Villaz-St-Pierre, 

SWITZERLAND; Guangdong OPT 

Technology Co., Ltd., Dongguan, 

PEOPLE’S REPUBLIC OF CHINA; 

Roboteq, Inc., Scottsdale, AZ; Uson L.P., 

Houston, TX; and Shanghai JAKA 

Robotics Ltd., Shanghai, PEOPLE’S 

REPUBLIC OF CHINA, have been added 

as parties to this venture. 

Also, Acuity Brands, Inc., Conyers, 

GA; Lanmark Controls Inc., 

Londonderry, NH; Tokyo Keiso Co., 

Ltd., Tokyo, JAPAN; Hangzhou Hikrobot 

Technology Co., Ltd., Hangzhou, 

PEOPLE’S REPUBLIC OF CHINA; 

Bayshore Networks, Inc., Durham, NC; 

and FACTS, Inc., Cuyahoga Falls, OH, 

have withdrawn as parties to this 

venture. 

In addition, JANOME Corporation has 

changed its name to Janome Sewing 

Machine Co., Ltd., Tokyo, JAPAN; 

KEBA Industrial Automation GmbH to 

KEBA AG, Linz, AUSTRIA; and NTI AG 

to LinMot, Spreitenbach, 

SWITZERLAND. 

No other changes have been made in 

either the membership or planned 

activity of the group research project. 

Membership in this group research 

project remains open, and ODVA 

intends to file additional written 

notifications disclosing all changes in 

membership. 

On June 21, 1995, ODVA filed its 

original notification pursuant to Section 

6(a) of the Act. The Department of 

Justice published a notice in the Federal 

Register pursuant to Section 6(b) of the 

Act on February 15, 1996 (61 FR 6039). 


jspears on DSK121TN23PROD with NOTICES1
2178 Federal Register / Vol. 87, No. 9 / Thursday, January 13, 2022 / Notices 

The last notification was filed with 

the Department on October 5, 2021. A 

notice was published in the Federal 

Register pursuant to Section 6(b) of the 

Act on October 22, 2021 (86 FR 58690). 

Suzanne Morris, 

Chief, Premerger and Division Statistics, 

Antitrust Division. 

[FR Doc. 2022–00613 Filed 1–12–22; 8:45 am] 

BILLING CODE 4410–11–P 

DEPARTMENT OF JUSTICE 

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—The Integrated Photonics 

Institute for Manufacturing Innovation 

Operating Under the Name of the 

American Institute for Manufacturing 

Integrated Photonics 

Notice is hereby given that, on 

November 23, 2021, pursuant to Section 

6(a) of the National Cooperative 

Research and Production Act of 1993, 

15 U.S.C. 4301 et seq. (‘‘the Act’’), the 

Integrated Photonics Institute for 

Manufacturing Innovation operating 

under the name of the American 

Institute for Manufacturing Integrated 

Photonics (‘‘AIM Photonics’’) has filed 

written notifications simultaneously 

with the Attorney General and the 

Federal Trade Commission disclosing 

changes in its membership. The 

notifications were filed for the purpose 

of extending the Act’s provisions 

limiting the recovery of antitrust 

plaintiffs to actual damages under 

specified circumstances. Specifically, 

Regents of the University of Minnesota, 

Minneapolis, MN; Buhler Inc. Leybold 

Optics, Cary, NC; and Spark Photonics 

Design, Inc., Waltham, MA, have been 

added as parties to this venture. 

No other changes have been made in 

either the membership or planned 

activity of the group research project. 

Membership in this group research 

project remains open, and AIM 

Photonics intends to file additional 

written notifications disclosing all 

changes in membership. 

On June 16, 2016, AIM Photonics 

filed its original notification pursuant to 

Section 6(a) of the Act. The Department 

of Justice published a notice in the 

Federal Register pursuant to Section 

6(b) of the Act on July 25, 2016 (81 FR 

48450). 

The last notification was filed with 

the Department on August 19, 2021. A 

notice was published in the Federal 

Register pursuant to Section 6(b) of the 

Act on October 5, 2021 (86 FR 55001). 

Suzanne Morris, 

Chief, Premerger and Division Statistics, 

Antitrust Division. 

[FR Doc. 2022–00581 Filed 1–12–22; 8:45 am] 

BILLING CODE 4410–11–P 

DEPARTMENT OF JUSTICE 

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—Medical Technology 

Enterprise Consortium 

Notice is hereby given that, on 

November 29, 2021, pursuant to Section 

6(a) of the National Cooperative 

Research and Production Act of 1993, 

15 U.S.C. 4301 et seq. (‘‘the Act’’), 

Medical Technology Enterprise 

Consortium (‘‘MTEC’’) has filed written 

notifications simultaneously with the 

Attorney General and the Federal Trade 

Commission disclosing changes in its 

membership. The notifications were 

filed for the purpose of extending the 

Act’s provisions limiting the recovery of 

antitrust plaintiffs to actual damages 

under specified circumstances. 

Specifically, Integration Innovation Inc., 

Huntsville, AL; HackerOne, San 

Francisco, CA; Advanced Materials and 

Devices, Inc., Reno, NV; Cimarron 

Software Services Inc.,Houston, TX; 

Delta Chase LLC., West Chester, OH; 

Virginia Commonwealth University, 

Richmond, VA; H&H Medical 

Corporation, Williamsburg, VA; 

Spectrohm Inc. Tysons Corner, VA; 

Rubix LS, Lawrence, MA; University of 

Florida, Gainesville, FL; Phagelux 

(Canada) Inc., Montre ́al, CAN; Next 

Science, LLC., Jacksonville, FL; 

BlackBox Biometrics, Inc. (B3) 

Rochester, NY; VitaCyte LLC., 

Indianapolis, IN; Synedgen, Inc., 

Claremont, CA; KeriCure Medical, 

Wesley Chapel, FL; Kurve Technology 

Inc., Lynnwood,WA; SweetBio, Inc. 

Memphis, TN; DLH Silver Spring, MD; 

Novel Technologies Holdings Limited, 

Manchester, NH; KERECIS Limited, 

Isafjordur, ISL; NanoOxygenic LLC., 

Dallas, PA; Georgia State University 

Research Foundation, Inc. Atlanta, GA; 

Retia Medical LLC., Valhalla, NY; 

AivoCode Inc. La Jolla, CA; Medical 

Informatics Corp., Houston, TX; 

Technatomy Corporation Fairfax, VA; 

Terida LLC. Pinehurst, NC; Appili 

Therapeutics, Inc., Halifax, CAN; 

Continuous Precision Medicine(CPM) 

Research, Triangle Park, NC; Overseas 

Strategic Consulting, Ltd, Philadelphia, 

PA; Vizbii Technologies, Inc., 

Charleston, SC; Anthem Engineering 

LLC., Elkridge,MD; Perfusion Medical, 

LLC. Reston, VA; New York University, 

New York, NY; Catharsis Productions, 

Chicago,IL; University of New 

Hampshire Durham, NH; Aldyn, Boston, 

MA; GEN–AVIV LLC., North Miami 

Beach, FL; NeuroFlow, Inc., 

Philadelphia, PA; Advancement 

Strategy, LLC., Columbia, MD.; Belle 

Artificial Intelligence Corporation, 

Cambridge, MA; Diagnoss Inc, Pomona, 

CA; San Diego State University, San 

Diego, CA; Dovel Technologies, 

McLean, VA; ASSURSEC, LLC., 

LEESBURG, VA; Rhode Island Hospital, 

Providence, RI; University of 

Connecticut, Storrs, CT; Alertgy, Inc. 

MELBOURNE, FL; Boston University, 

Boston, MA; MBio Diagnostics, Inc. dba 

LightDeck Diagnostics, Boulder, CO; 

Pacific Institute for Research and 

Evaluation, Beltsville, MD; Tactical 

Medical Solutions, LLC., Anderson, SC; 

ViiNetwork, Inc., ViiMed, Washington, 

DC; Renaissance Biotech, LLC., Malibu, 

CA; Bio1 Systems, Inc., San Carlos, CA; 

DataRobot, Boston, MA; Knowesis Inc., 

Fairfax, VA; MassBiologics of the 

UMMS, Boston, MA; SOLUTE Inc., San 

Diego, CA; Aktiv Pharma Group, 

Broomfield, CO; Bettermeant, Inc., 

Berkeley, CA; SanMelix Laboratories, 

Inc., Hollywood, FL; Viscus Biologics 

LLC., Cleveland, OH; Guidehouse Inc. 

Falls Church, VA; Movement Rx 

Physical Therapy, P.C., San Diego, CA; 

Promethean LifeSciences, Inc., 

Pittsburgh, PA; Tygrus LLC., Troy, MI; 

MiMedx Group, Inc., Marietta, GA; 

Neomatrix Therapeutics, Inc., Stony 

Brook, NY; PuraLab LLC., Wilsonville, 

OR; InterSystems Corporation, 

Cambridge, MA; Full Spectrum Omega, 

Inc., Los Angeles, CA; Rockland 

Technimed Limited, Mahwah, NJ; 

MediWound, Ltd., Yavne, ISR; 

Primmune Therapeutics, Inc., San 

Diego, CA; Western Michigan University 

Homer Stryker M.D. School of 

Medicine, Kalamazoo, MI; Emmes 

Company LLC., Rockville MD; Canvas 

Incorporated, Huntsville, AL; Purgo 

Scientific, LLC., South Jordan, UT; 

Dascena, Houston, TX; Through The 

Cords LLC., Salt Lake City, UT; Armed 

Forces Services Corporation dba 

Magellan Federal, Arlington, VA; 

Immuron Limited, Victoria, AUS; 

Terumo BCT Biotechnologies, LLC., 

Lakewood, CO; TourniTek, Seattle, WA; 

West Therapeutic Development, LLC., 

Northbrook, IL; Maryland Development 

Center, Baltimore, MD; Tessonics 

Medical Systems Inc., BIRMINGHAM, 

MI; Vir Biotechnology, San Francisco, 

CA; Wound Exam Corp., Beverly Hills, 

CA; Creare LLC., Hanover, NH; Drexel 


jspears on DSK121TN23PROD with NOTICES1